IRIDEX (IRIX) Q2 FY26 earnings call

IRIDEX achieved positive cash flow in Q2 FY26, reflecting significant cost structure transformation and working capital management. While the glaucoma business showed strong probe-led growth, the retina segment faced temporary market and operational challenges, leading to an overall revenue decline. The company is focused on strengthening execution and supply chain ahead of headquarters relocation and manufacturing transitions, reaffirming its full-year revenue guidance.